Discover
SLXN
Silexion Therapeutics Ltd.
1.12
2 x 1.09
8 x 1.10
bid
ask
-
0.38
25.33%
01:40 PM
timesize
| Ytd | -94.17% | |
| 1y | -98.53% |
1.05
day range
1.42
1.05
52 week range
80.00
| Open | 1.42 | Prev Close | 1.50 | Low | 1.05 | High | 1.42 | Mkt Cap | 469.28K |
| Vol | 302.58K | Avg Vol | 675.59K | EPS | -39.55 | P/E | -0.03 | Forward P/E | -3.95 |
| Beta | -0.25 | Short Ratio | 0.23 | Inst. Own | 8.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 2.85 | 200-d Avg | 14.33 | 1yr Est | 9.00 |
| Income Statement | |||
| Operating Expenses | 2.75M | ||
| Research and Development Expense | 1.37M | ||
| Selling, General and Administrative Expense | 1.38M | ||
| Operating Income | -2.75M | ||
| Interest Expense | -16.00K | ||
| Net Income | -2.73M | ||
| Net Income Common Stock | -2.73M | ||
| Net Income Common Stock (USD) | -2.73M | ||
| Consolidated Income | -2.73M | ||
| Earnings per Basic Share | -8.50 | ||
| Earnings per Basic Share (USD) | -8.50 | ||
| Earnings per Diluted Share | -8.50 | ||
| Earning Before Interest & Taxes (EBIT) | -2.75M | ||
| Earning Before Interest & Taxes (USD) | -2.75M | ||
| Weighted Average Shares | 323.04K | ||
| Weighted Average Shares Diluted | 323.04K | ||
| Balance Sheet | |||
| Cash and Equivalents | 2.44M | ||
| Cash and Equivalents (USD) | 2.44M | ||
| Investments | 58.00K | ||
| Investments Non-Current | 58.00K | ||
| Current Assets | 4.07M | ||
| Property, Plant & Equipment Net | 403.00K | ||
| Total Assets | 4.60M | ||
| Debt Current | 1.74M | ||
| Total Debt | 1.99M | ||
| Current Liabilities | 4.06M | ||
| Debt Non-Current | 251.00K | ||
| Total Liabilities | 4.31M | ||
| Accumulated Retained Earnings (Deficit) | -57.90M | ||
| Shareholders Equity | 291.00K | ||
| Shareholders Equity (USD) | 291.00K | ||
| Assets Non-Current | 537.00K | ||
| Total Debt (USD) | 1.99M | ||
| Liabilities Non-Current | 251.00K | ||
| Trade and Non-Trade Payables | 1.76M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.00K | ||
| Net Cash Flow from Financing | 83.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -3.56M | ||
| Issuance (Purchase) of Equity Shares | 83.00K | ||
| Net Cash Flow from Operations | -3.65M | ||
| Effect of Exchange Rate Changes on Cash | -14.00K | ||
| Share Based Compensation | 345.00K | ||